Biogen, felzartamab and kidney transplant
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...
Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...
The stock's fall snapped a seven-day winning streak.
Multiple Sclerosis Therapeutics market is estimated to be valued at USD 31.39 Bn in 2025 and is expected to reach USD 41.89 Bn by 2032, exhibiting a CAGR of 4%. BURLINGAME, CA, UNITED STATES, March 13 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback